Holen Sie sich die Stockscreener-App
1.18
0.85%
0.01
Handel nachbörslich:
1.27
0.09
+7.63%
Schlusskurs vom Vortag:
$1.17
Offen:
$1.17
24-Stunden-Volumen:
59,144
Relative Volume:
0.80
Marktkapitalisierung:
$81.15M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-9.22M
KGV:
-4.0453
EPS:
-0.2917
Netto-Cashflow:
$-4.60M
1W Leistung:
-4.07%
1M Leistung:
+5.36%
6M Leistung:
-7.09%
1J Leistung:
-15.11%
1-Tages-Spanne:
$1.17
$1.22
1-Wochen-Bereich:
$1.15
$1.24
52-Wochen-Spanne:
$0.8885
$2.091
Telomir Pharmaceuticals Inc Stock (TELO) Company Profile
Firmenname
Telomir Pharmaceuticals Inc
Sektor
Branche
Telefon
786-396-6723
Adresse
100 SE 2ND ST, MIAMI
Compare TELO vs VRTX, MRNA, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TELO
Telomir Pharmaceuticals Inc
|
1.18 | 84.59M | 0 | -9.22M | -4.60M | -0.2917 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Telomir Pharmaceuticals Inc Stock (TELO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-21 | Eingeleitet | Rodman & Renshaw | Buy |
Telomir Pharmaceuticals Inc Aktie (TELO) Neueste Nachrichten
Telomir Pharmaceuticals targets global partnerships after FDA clearance for Telomir-Zn - Traders Union
Telomir Pharmaceuticals scientific advisor named plenary lecturer at Tokyo women health event - Traders Union
Experimental drug found to slow bone cancer cell growth in dog and human lab tests - DVM360
Telomir announces preclinical study on AMD treatment candidate - Investing.com
Telomir announces preclinical study on AMD treatment candidate By Investing.com - Investing.com Nigeria
Telomir-Zn Preclinical Data Highlight Retinal Regeneration Potential - TipRanks
Vision gains in fish study link Telomir (NASDAQ: TELO) eye data to its cancer program - Stock Titan
Maxim Group Initiates Telomir Pharmaceuticals(TELO.US) With Buy Rating, Announces Target Price $4 - Moomoo
Telomir Announces Peer-Reviewed Publication Showing - GlobeNewswire
Telomir (TELO) investors approve all 2026 votes - Stock Titan
Form 8K Telomir Pharmaceuticals Inc For: 14 September By Investing.com - Investing.com Nigeria
Telomir unveils new preclinical data for Telomir-Zn - TipRanks
Telomir Pharmaceuticals Announces Research Demonstrating In-Vitro Anti-Cancer Activity Of Telomir-Zn In Human And Canine Osteosarcoma Models - marketscreener.com
Telomir Announces Research with The Ohio State University - GlobeNewswire
Telomir Pharmaceuticals Inc. (TELO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Telomir Pharmaceuticals Inc (TELO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Telomir Pharmaceuticals (TELO) Climbs 3.81% as Micro-Cap Biotech Momentum BuildsMomentum Surge Alerts - siam.in
Telomir Pharmaceuticals (TELO): John Paul DeJoria reports 5.169% ownership stake - Stock Titan
TELO Q4 2025 Earnings: Deep EPS Miss Underscores Pre-Revenue ChallengesFinancial Data - vinanet.vn
Telomir Flags Substantial Doubt About Ability to Continue as Going Concern - Minichart
Telomir Pharmaceuticals (NASDAQ:TELO) Releases Quarterly Earnings Results - MarketBeat
Telomir Pharmaceuticals | 10-Q: Q2 2026 Earnings Report - Moomoo
Telomir-Zn shows promise for iron-addicted cancers - BioWorld News
Telomir Pharmaceuticals (NASDAQ:TELO) Stock Price Down 3.4%Should You Sell? - MarketBeat
Telomir-Zn Preclinical Data Support Advancement in TNBC - TipRanks
Telomir Pharmaceuticals Announces Peer-Reviewed Publication of Preclinical Telomir-Zn Data Showing Tumor Suppression in Prostate and Triple-Negative Breast Cancer Models - Quiver Quantitative
Telomir Announces Peer-Reviewed Publication Demonstrating Telomir-Zn Suppresses Tumor Growth in TNBC and Prostate Cancer Models - Yahoo Finance
Telomir Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Aminov Erez - Moomoo
Telomir Pharmaceuticals (TELO) Slides 3.4% to $1.21 as Key Support Level Comes into FocusCalendar Spread Trade - careplusvn.com
Telomir Pharmaceuticals Inc. (TELO) Q4 2025 Earnings: Wider-than-Expected Loss Amid Pre-Revenue R&D Stage - dars.gov.et
Telomir Pharmaceuticals, Inc. Common Stock (NASDAQ: TELO) Stock Price, News & Analysis - Kalkine
Telomir Pharmaceuticals (TELO) grants 50,000 stock options to director - Stock Titan
TELO|Telomir Pharmaceuticals Inc|Price:1.230|Chg%:+0.080 - TradingKey
Telomir Pharmaceuticals (TELO) awards director 50,000 stock options at $1.34 - Stock Titan
Telomir Pharmaceuticals Inc (TELO) Institutional Confidence - TradingKey
Telomir Pharmaceuticals Inc (TELO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Telomir Pharmaceuticals Inc (TELO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Telomir Pharmaceuticals Inc (TELO) Cash Flow - TradingKey
Telomir Pharmaceuticals Inc (TELO) Balance Sheet - TradingKey
Telomir Pharmaceuticals Inc (TELO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Telomir Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:TELO - TradingView
Telomir Pharmaceuticals Inc (TELO) Income Statement - TradingKey
Telomir Pharmaceuticals Inc (TELO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
12 Health Care Stocks Moving In Tuesday's Intraday Session - Sahm
TELO Q4 2025 Earnings: Wider-than-Expected Loss Amid Early-Stage Drug DevelopmentSaaS Earnings Trends - vinanet.vn
TELO Q4 2025 Earnings: Wider-than-Expected Loss but Stock Surges 17.5% Amid Strategic ProgressForward EPS Estimate - dars.gov.et
Andriy Mushak Net Worth (2026) - GuruFocus
TELO Q4 2025 Earnings: EPS Misses Estimates Markedly, No Revenue YetConsensus Miss Rate - careplusvn.com
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
TELO Q4 2025 Earnings: EPS Misses Estimates by Wide Margin as Pre-Revenue Biotech Reports No RevenueEarnings Power Value - DonanımHaber
Finanzdaten der Telomir Pharmaceuticals Inc-Aktie (TELO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.05%
0.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):